Kamada Ltd. (TLV:KMDA)
| Market Cap | 1.53B +14.1% |
| Revenue (ttm) | 603.87M +12.6% |
| Net Income | 76.52M +22.0% |
| EPS | 1.32 +22.7% |
| Shares Out | 57.71M |
| PE Ratio | 20.14 |
| Forward PE | 18.51 |
| Dividend | 0.90 (3.39%) |
| Ex-Dividend Date | Nov 19, 2026 |
| Volume | 152,153 |
| Open | 2,600.00 |
| Previous Close | 2,623.00 |
| Day's Range | 2,579.00 - 2,670.00 |
| 52-Week Range | 1,956.00 - 2,890.00 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 9, 2026 |
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f... [Read more]
Full Company ProfileFinancial Performance
In 2025, Kamada's revenue was $180.46 million, an increase of 12.12% compared to the previous year's $160.95 million. Earnings were $20.20 million, an increase of 39.66%.
Financial numbers in USD Financial StatementsNews
Kamada Transcript: Stifel 2026 Healthcare Conference 2026
First-nine-month results showed growth across financial metrics, with strong cash generation and dividends. Growth plans include biosimilar launches, plasma sales and a potential acquisition, while margin gains are supported by scale and in-house manufacturing.
Kamada price target raised to $12 from $11 at Stifel
Stifel raised the firm’s price target on Kamada (KMDA) to $12 from $11 and keeps a Buy rating on the shares. Continuing to execute across its globally diversified platform, Kamada…
Kamada (KMDA) Q3 2026 Earnings Call Transcript
Nine-month results hit records as management lifted full-year guidance and signed a plasma deal.
Kamada Ltd. Reports Record First Nine Months 2026 Financial Results and Declares Cash Dividend of $0.14 Per Share
Kamada Ltd. reported total revenues of $52.0 million for the third quarter of 2026, up 11% compared to $47.0 million in the third quarter of 2025. Net income for the third quarter of 2026 was $8.0 mil...
Kamada Q3 Earnings Call Highlights
Kamada NASDAQ: KMDA raised its 2026 revenue and adjusted EBITDA guidance after reporting double-digit third-quarter growth, as demand increased for its KEDRAB rabies treatment and other products.
Kamada Earnings Call Transcript: Q3 2026
Nine-month revenue reached $152.2M (+12% YoY), adjusted EBITDA $40.9M (+20%) and net income $21.4M (+29%); FY26 guidance rose to $205M–$208M revenue and $52M–$54M adjusted EBITDA. KEDRAB demand and distribution expansion support projected double-digit profitable growth in 2027.
Kamada Earnings release: Q3 2026
Kamada released its Q3 2026 earnings on November 9, 2026, summarizing the period's financial results.
Kamada reports Q3 EPS 14c, consensus 13c
Reports Q3 revenue $52.03M vs. $47.01M last year. “During the third quarter of 2026, we continued the strong operational and financial performance we have demonstrated throughout the year, with double...
Kamada raises FY26 revenue view to $205M-$208M from $200M-$205M
The company said, “Kamada (KMDA) is increasing its 2026 annual financial guidance to total revenues in the range of $205 million to $208 million and adjusted EBITDA in the range…
Kamada Reports Record-High First Nine Months 2026 Financial Results; Increases 2026 Annual Guidance and Projects Double-Digit Growth in Revenues and Profitability in 2027
REHOVOT, Israel, and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for ...
Kamada Declares Cash Dividend of $0.14 Per Share; The Company Continues its Record-High Year
REHOVOT, Israel and HOBOKEN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Kamada to Announce Third Quarter and Nine Months Ended September 30, 2026, Financial Results on November 9, 2026
REHOVOT, Israel and HOBOKEN, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Kamada Announces Participation in the Stifel 2026 Healthcare Conference and the Jefferies Global Healthcare Conference in London During November 2026
REHOVOT, Israel and HOBOKEN, N.J., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd.
Kamada launches two new biosimilar products in Israel
Kamada (KMDA) announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products. The two…
Kamada Announces Expansion of Biosimilars Portfolio with the Launch of Two Additional Products in Israel
Company Expects Growing Biosimilar Product Portfolio, Commercialized in Israel and the MENA Region, to Generate Approximately $10 Million in Annual Revenue in 2028 and Approximately $20 Million-$25 Mi...
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth
Kamada NASDAQ: KMDA outlined its growth strategy, product portfolio and financial outlook during a company presentation, emphasizing demand for specialty plasma-derived therapies and a plan to expand ...
Kamada Transcript: Small-Cap Virtual Conference
Double-digit growth continues, with 2026 revenue and EBITDA on track and strong cash generation. Specialty plasma therapies, expanded distribution, and a robust product portfolio drive performance, while new plasma sales agreements and M&A opportunities support future growth.
Kamada Confirms KedRAB Supply As U.S. Rabies Exposures Increase
(RTTNews) - Kamada Ltd. (KMDA; KMDA.TA) confirmed that it maintains sufficient inventory and manufacturing capacity to meet increased U.S. demand for KedRAB, following a September 10, 2026 Health Advi...
Kamada confirms sufficient KedRAB supply amid increased demand
Kamada (KMDA) confirmed that it maintains sufficient KedRAB supply and manufacturing capacity to meet increased demand for the product in the United States. The confirmation follows a Health Advisory ...
CDC Highlights Significant Increase in U.S. Rabies Exposures and Anti-Rabies Immunoglobulin Utilization; Kamada Confirms Sufficient KedRAB® Supply to Meet Increased Demand
U.S. Centers for Disease Control and Prevention (CDC) Reports a Significant Year-Over-Year Increase in Nationwide Rabies Exposures and Rabies Immunoglobulin Utilization KedRAB is One of Only Two FDA-A...
Kamada Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Double-digit growth continues with $200–$205 million in projected 2024 sales and strong profitability. Expansion is driven by a diverse plasma-derived product portfolio, biosimilar launches, international reach, and a $50 million plasma sales contract, with M&A opportunities under review.
Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference
REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for...
Kamada Registration statement: Registration filing
Kamada filed a registration statement on September 9, 2026, providing details about a securities offering with the SEC.
Kamada files to sell $50M of ordinary shares
07:07 EDT Kamada (KMDA) files to sell $50M of ordinary shares
Kamada Updates on Withholding Tax Procedures on Previously Announced Cash Dividend to Shareholders
REHOVOT, Israel and HOBOKEN, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed product...